Core Insights - The "China Pharmaceutical Valley" in Daxing is actively promoting international expansion for pharmaceutical companies, with over 20 companies successfully entering overseas markets and hundreds of products launched internationally [2][3] - The Daxing Biopharmaceutical Industry Base has established a comprehensive "outbound service platform" to support companies in their international endeavors, integrating resources from government, industry organizations, and overseas institutions [3][4] - The government is focused on addressing challenges faced by companies in international markets, providing full-process guidance on overseas registration, data compliance, and intellectual property layout [4] Group 1: International Expansion - Daxing has hosted the "3rd China-Germany Cross-Border Pharmaceutical Health Industry Cooperation Exchange Conference," signaling a commitment to accelerate overseas market expansion for pharmaceutical enterprises [1] - Companies like Baiyao and Minhai Biotech have reported significant international sales, with Baiyao achieving nearly 70% of its sales from overseas markets [2] - Tongrentang, a traditional Chinese medicine leader, reported overseas revenue of 592 million yuan, a year-on-year increase of 21.52% [2] Group 2: Supportive Infrastructure - The upgraded "outbound service platform" has enabled companies like Amite Medical to secure larger overseas orders, moving beyond small transactions [3] - The platform fosters collaboration among companies with outbound experience, allowing for shared resources and channels to facilitate international market entry [3] - The Daxing Biopharmaceutical Base aims to enhance its vitality through increased openness and support for companies in developing global perspectives and capabilities [3]